PDX Portal

Model Details

Patient Information for Model: HCI-012

Model Contact

Model: HCI-012
Model Contact: Alana Welm
Institution: HCI Breast PDX Program
Email: Alana.Welm@hci.utah.edu

Patient Information

Clinical Timeline

Color Keys:

Positive

Negative

N/A

Clinical Information at Collection

Clinical Biomarkers/Mutations at Collection

Pathology Information at Collection

Model Information for Model: HCI-012

Model Details - Initial Implantation of Patient Tissue

Biomarkers & Mutations

Model Details - Acceptable Conditions for Passaging

Mutations (Cancer Gene Census List)

Mutation data is currently not available.

CNV

Histology Information for Model: HCI-012

There are no histology images for this model.

Metastasis Information for Model: HCI-012

Patient

PDX

Abdomen

Adrenal gland

Bone

Bones

Brain

CTC

Chest

Chest wall

Contralateral Breast

Dura

Fallopian Tubes

Head

Kidney

Liver

Lung

Lymph node

Lymph nodes

Neck

Ovary

Pancreas

Pericardium

Peritoneal cavity

Peritoneum

Pleura

Pleural effusion

Shoulder

Skin

Spine

Spleen

Thoracic Spine

Thymus

Patient Treatment Information for Model: HCI-012

Event Id	Treatment	Treatment Setting	Age at Start	Age at End	Duration
8	Letrozole	Neoadjuvant	48.01	50.25	818 days
9	Abraxane, 5-fluorouracil, Cyclophosphamide, Aldesleukin/Proleukin, Interleukin 2, Epirubicin, Leucovarin, Methotrexate	Neoadjuvant	48.33	50.33	730 days
13	Doxorubicin	Neoadjuvant	50.25	50.33	29 days
14	Capecitabine	Neoadjuvant	50.33	50.41	29 days
15	Herceptin, Vinerolbine	Neoadjuvant	50.25	50.67	153 days
17	Capecitibine/Lapatinab	Neoadjuvant	50.67	50.91	88 days
19	Radiation to the neck and lung	Neoadjuvant	50.91	51.0	33 days